Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock - CYCCP STOCK NEWS

Cyclacel Pharmaceuticals announced it received a notice from the European Patent Office intending to grant a new patent for plogosertib pharmaceutical compositions. This patent will extend the exclusivity of plogosertib, a PLK1 inhibitor, until August 2040, excluding any extensions. The patent strengthens Cyclacel’s portfolio and supports a new oral formulation of plogosertib with improved bioavailability. Cyclacel aims to evaluate plogosertib for ARID1A- and/or SMARCA-mutated cancers. Additionally, its lead drug candidate, fadraciclib, is undergoing a proof-of-concept study in patients with solid tumors and T-cell lymphoma, with initial data expected in the second half of 2024.

Cyclacel Pharmaceuticals announced preclinical data for fadraciclib, a CDK2/9 inhibitor, demonstrating efficacy in metastatic colorectal cancer (CRC) models. Presented at the 2024 ASCO Annual Meeting, the study showed that fadraciclib significantly inhibited tumor growth, induced apoptosis, and triggered anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDXs). The research highlighted fadraciclib's superiority over standard chemotherapy and palbociclib in CRC models. Cyclacel's CEO, Spiro Rombotis, emphasized fadraciclib’s broad potential in multiple tumor types. Initial proof of concept data is expected in the second half of 2024.

Cyclacel Pharmaceuticals presented new clinical data on their CDK2/9 inhibitor, fadraciclib, at the 2024 ASCO Annual Meeting. The Phase 1 study, CYC065-101, involved heavily pretreated patients with various cancers, demonstrating clinical benefits in endometrial, lung, ovarian, pancreatic cancers, and T-cell lymphoma. Fadraciclib showed good tolerance with the most common adverse events being nausea, vomiting, and diarrhea. Pharmacokinetic (PK) and pharmacodynamic (PD) data indicated dose proportionality and efficacy in CDKN2A/B suppression. The Phase 2 proof of concept part is currently enrolling patients with CDKN2A/B loss or T-cell lymphoma, with initial results expected in the second half of 2024.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported its first quarter 2024 financial results and provided a business update. Key highlights include enrolling patients in the Phase 2 proof-of-concept (PoC) study of oral fadraciclib, a CDK2/9 inhibitor, with data to be presented at the ASCO Annual Meeting. The company received $8.0 million from a private placement, bolstering its balance sheet. As of March 31, 2024, Cyclacel had $9.9 million in pro forma cash and cash equivalents, including $0.8 million from the UK R&D tax credit. The net loss for Q1 2024 was $2.9 million, a decrease from $5.8 million in Q1 2023. R&D expenses were $2.8 million compared to $5.7 million last year. The company plans to report key data from its ongoing clinical trials later this year.

Cyclacel Pharmaceuticals, Inc. will release its first quarter 2024 financial results on May 14, 2024. The company focuses on developing innovative cancer treatments and will host a conference call and webcast to discuss the results.

Cyclacel Pharmaceuticals, a biopharmaceutical company, closed an $8.0 million private placement under NASDAQ rules, offering shares of common stock, series A warrants, and short-term series B warrants. The gross proceeds were $8.0 million, with H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.

Cyclacel Pharmaceuticals, Inc. announced an $8.0 million private placement under Nasdaq rules, offering shares of common stock and warrants to purchase more shares at a fixed price. The placement is expected to close on May 2, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.

Cyclacel Pharmaceuticals, Inc. announces new clinical, PK, and PD data from fadraciclib monotherapy studies at ASCO Annual Meeting, supporting ongoing development program for cancer patients.

Cyclacel Pharmaceuticals, Inc. announces fourth quarter and full year 2023 financial results, updates on fadraciclib and plogosertib development, and upcoming Phase 2 proof of concept studies. The company is on track to start oral fadraciclib Phase 2 in 1H 2024 and expects to report final data from fadraciclib 065-101 dose escalation. Preclinical data supports precision medicine strategy in ARID1A- and SMARCA-mutated cancers. Management will host a conference call at 4:30 pm ET today.